View Article

Abstract

The groundbreaking TEMPO 3:4 trial, which served as the basis for tolvaptan's approval, represented a revolution in the treatment of autosomal dominant polycystic kidney disease (ADPKD). Through this advancement, patient management for ADPKD has evolved from using broad strategies to stop the progression of chronic kidney disease to focusing on disease-specific mechanisms. Evidence-based strategies to start treatment only in patients with quickly worsening disease are essential, though, given the long-term nature of this medication and associated side effects. The European Renal Association (ERA) policy statement, released in 2016, was the first society-based guideline on the usage of tolvaptan and has been a popular resource for nephrologists when making decisions. Since then, there has been a significant accumulation of practical knowledge regarding the use of tolvaptan in ADPKD.

Keywords

ADPKD; polycystic kidney disease; position statement; tolvaptan; vasopressin V2 receptor antagonist

Reference

  1. Zilberberg MD, Exuzides A, Spalding J, et al. Epidemiology, clinical and economic outcomes of admission hyponatremia among hospitalized patients. Curr Med Res Opin. 2008;24(6):1601–1608.
  2. Verbalis JG, Goldsmith SR, Greenberg A, et al. Hyponatremia treatment guidelines 2007: Expert panel recommendations. Am J Med. 2007;120(11A):S1–S21. 
  3. Rockville, MD: Otsuka America Pharmaceutical, Inc.; May 2009. Samsca (tolvaptan), package insert. 
  4. Schrier RW, Gross P, Gheorghiade M, et al.for the SALT Investigators Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:2099–2112.
  5. Gheorghiade M, Konstam MA, Burnett JC, et al.for the EVEREST Investigators Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST Clinical Status Trials. JAMA. 2007;297:1332–1343.
  6. Konstam MA, Gheorghiade M, Burnett JC, et al.for the EVEREST Investigators Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST Outcome Trial. JAMA. 2007;297:1319–1331.
  7. Schrier RW, Gross P, Gheorghiade M, et al.for the SALT Investigators Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:2099–2112. 
  8. Gheorghiade M, Konstam MA, Burnett JC, et al.for the EVEREST Investigators Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST Clinical Status Trials. JAMA. 2007;297:1332–1343
  9. Konstam MA, Gheorghiade M, Burnett JC, et al.for the EVEREST Investigators Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST Outcome Trial. JAMA. 2007;297:1319–1331.
  10. Structure of Tolvaptan - https://web.chemdoodle.com/demos/iupac-naming#customise-template
  11. Indian Pharmacopoeia - 2022,  Ninth Edition, Volume – III, Page number: 3832, Chebrolu Hanumaiah Institute of Pharmaceutical Sciences, Chowdavaram, Guntur, Andhra Pradesh, India.

Photo
Kondeti Venkata Surya Siva Kumar
Corresponding author

Department of Pharmacology and Pharmaceutics, Chebrolu Hanumaiah Institute of Pharmaceutical Sciences, Chandramoulipuram, Chowdavaram, Guntur, Andhra Pradesh – 522019, India

Photo
Saripella Latha Sree
Co-author

Department of Pharmacology and Pharmaceutics, Chebrolu Hanumaiah Institute of Pharmaceutical Sciences, Chandramoulipuram, Chowdavaram, Guntur, Andhra Pradesh – 522019, India

Photo
Saripella Jaya Sree
Co-author

Department of Pharmacology and Pharmaceutics, Chebrolu Hanumaiah Institute of Pharmaceutical Sciences, Chandramoulipuram, Chowdavaram, Guntur, Andhra Pradesh – 522019, India

Kondeti Venkata Surya Siva Kumar, Saripella Latha Sree and Saripella Jaya Sree, Tolvaptan - Vasopressin Antagonist for Hyponatremia, Int. J. in Pharm. Sci., 2023, Vol 1, Issue 8, 1-8. https://doi.org/10.5281/zenodo.8206257

More related articles
Promoting Rational Use of Medicines: A Multifacete...
Dhanshree Mohite , Kavita Saner, P. N. Sable, Nirmala Parmar, Man...
Down Syndrome: An Insight Of The Disease...
Musku Srivani, Gudivada Himaja Lakshmi, Aashutosh Sinwal, Ishu, M...
Zebrafish in Neurotoxicity Research: A Comprehensi...
Dr. Sandhiya, Dr. N. Deepa, Hemapriya, Jananee, Dr. Anamika P. K....
Mucormycosis: Diagnosis, Treatment And Future Direction...
Pratik Borawake, Akash Doke, Siddhi Gavali , ...
A Review: Natural Anti-Obesity Agents...
Yashraj Narake, Omkar Gongane, Tejas Kapase , Pritam Salokhe, Sachin Navale, Nilesh Chougule, ...
Related Articles
Analytical Quality by Design: A Systematic Review ...
Wagh Sneha Sunil , R. B. Darade, ...
Polycystic Ovary Syndrome: Insights And Advances In Diagnosis And Management ...
P. Lazaru, Dr. J. N. Suresh Kumar, K. Sai Teja Sree, SK. Mansoor, M. Siva Kumar, S. Venkata Sakshi, ...
Recent Advances And Emergency Trends In Anticoagulant Therapy...
Bhavani Suba Niranjana, Julliyan Dilleban , Deephiha Elango, Balakrishnan karuppiah, ...
Promoting Rational Use of Medicines: A Multifaceted Approach ...
Dhanshree Mohite , Kavita Saner, P. N. Sable, Nirmala Parmar, Manisha Sirvi, Vikas Mohite , ...
More related articles
Promoting Rational Use of Medicines: A Multifaceted Approach ...
Dhanshree Mohite , Kavita Saner, P. N. Sable, Nirmala Parmar, Manisha Sirvi, Vikas Mohite , ...
Down Syndrome: An Insight Of The Disease...
Musku Srivani, Gudivada Himaja Lakshmi, Aashutosh Sinwal, Ishu, Mohit Nair, Smrithimol Baby, ...
Zebrafish in Neurotoxicity Research: A Comprehensive Review...
Dr. Sandhiya, Dr. N. Deepa, Hemapriya, Jananee, Dr. Anamika P. K., ...
Promoting Rational Use of Medicines: A Multifaceted Approach ...
Dhanshree Mohite , Kavita Saner, P. N. Sable, Nirmala Parmar, Manisha Sirvi, Vikas Mohite , ...
Down Syndrome: An Insight Of The Disease...
Musku Srivani, Gudivada Himaja Lakshmi, Aashutosh Sinwal, Ishu, Mohit Nair, Smrithimol Baby, ...
Zebrafish in Neurotoxicity Research: A Comprehensive Review...
Dr. Sandhiya, Dr. N. Deepa, Hemapriya, Jananee, Dr. Anamika P. K., ...